{"id":"E13","lang":"en","question":"What is GlycoNex’s GNX102 and which clinical stage has it reached?","answer":[{"text":"GNX102 is GlycoNex’s humanized monoclonal antibody targeting tumor-associated glycan structures; its registered study NCT04250597 was Phase 1.","fact_ids":["f1","f2"]},{"text":"The record last updated on May 6, 2024 lists the trial as TERMINATED and says the expansion phase was not performed following the sponsor’s business decision after the maximum tolerated dose was reached.","fact_ids":["f3","f4"]},{"text":"GlycoNex’s current pipeline separately lists GNX1021 as a clinical-stage ADC, so its Phase 1 status should not be assigned to GNX102.","fact_ids":["f5"]}],"facts":[{"id":"f1","claim":"Modality and target","value":"Humanized monoclonal antibody targeting novel tumor glycan structures","as_of":"2024-05-06","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","quote":"GNX102 is a humanized monoclonal antibod"},{"id":"f2","claim":"Registered phase","value":"NCT04250597; PHASE1","as_of":"2024-05-06","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","quote":"PHASE1"},{"id":"f3","claim":"Trial status","value":"TERMINATED; last posted update 2024-05-06","as_of":"2024-05-06","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","quote":"TERMINATED"},{"id":"f4","claim":"Reason stopped","value":"Maximum tolerated dose reached; expansion not performed per sponsor business decision","as_of":"2024-05-06","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","quote":"Maximum tolerated dose reached"},{"id":"f5","claim":"Separate ADC program","value":"GNX1021; Phase 1","as_of":"2026-10-22","source":"https://glyconex.com.tw/pipeline/","quote":"clinical-stage GNX1021"}],"undisclosed":{"text":"The checked GNX102 registry record does not disclose a restart date; GNX1021’s separate ADC progress is not evidence of a restarted GNX102 trial.","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","as_of":"2026-10-22","quote":"GNX102","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["Registered phase and termination are confirmed; no restart or later GNX102 study was verified."]}